# Repurposing Antidiabetic Medications for Parkinson’s Disease: Focus on Biomarker Strategies for Disease Modification

## TL;DR

This paper reviews how antidiabetic drugs might be repurposed to treat Parkinson’s disease, focusing on biomarkers that could help assess their effectiveness.

## Contribution

The paper provides a consolidated review of biochemical biomarkers used to evaluate antidiabetic medications as potential disease-modifying therapies for Parkinson’s disease.

## Key findings

- Antidiabetic drugs show potential neuroprotective effects in Parkinson’s disease.
- Biomarker research is crucial for evaluating the efficacy of these drugs in modifying disease progression.
- Current research lacks consistency in biomarker evaluation methods.

## Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder. It shares many pathophysiologic similarities with type 2 diabetes mellitus (T2DM). Numerous studies have explored the repurposing of antidiabetic medications for their potential neuroprotective effects in PD. There has not been a consolidated review of the biochemical biomarkers that have been evaluated across antidiabetic medications. This review aims to assess the current landscape of biomarker research in evaluating the efficacy of these antidiabetic agents as disease-modifying therapies in PD. We examine the molecular mechanisms targeted by these drugs, the biomarkers used to assess their effects, and the outcomes of clinical trials. This review hopes to identify gaps in current research and enhance the evaluation of antidiabetic medications in PD.